Liz Essley Whyte, Wall Street Journal

Liz Essley Whyte

Wall Street Journal

Washington, DC, United States

Contact Liz

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Start free trial

  • Unknown
  • Wall Street Journal
  • Moneyish
  • Center for Public Integrity
  • NPR

Past articles by Liz:

The Price of First Gene Therapy for Muscular Dystrophy: $3.2 Million

The drug, from Sarepta Therapeutics, promises to repair the defective gene at the root of the fatal disorder, but is expected to cost millions of dollars. → Read More

Next Covid Shots in the U.S. Will Target Omicron Offshoot XBB.1.5

The FDA tells drugmakers to update their vaccines for fall to take aim at the widespread strain specifically. → Read More

FDA Allows Imports of China-Made Chemotherapy to Ease U.S. Shortage

The agency said it would allow Qilu Pharmaceutical to ship into the U.S. a chemotherapy injection known as cisplatin, even though the product hasn’t been FDA approved and the vials are labeled in Chinese. → Read More

FDA Warns About Safety of Custom-Made Ozempic

Some people have turned to pharmacies to make a solution containing the active ingredient, semaglutide. → Read More

Next Covid Boosters to Target New Strain

Health authorities and vaccine makers are moving toward targeting the next shot on a form of the XBB strain that is now circulating widely in the U.S. → Read More

Baby-Formula Makers Face FTC Investigation for Collusion

The agency is investigating whether any formula manufacturers coordinated before bidding for state contracts. → Read More

Abbott facing criminal investigation over baby-formula plant operations

The Justice Department is investigating conduct at the Abbott Laboratories infant-formula plant in Sturgis, Mich., that led to its shutdown last year and... → Read More

Little-Known Abortion Pill Maker Faces Scrutiny

The debate over medication abortions draws in the lone U.S. manufacturer of brand-name mifepristone. → Read More

FDA Planning to Allow Clinical Trials of Pig-Organ Transplants

Such a move by the Food and Drug Administration could be an important step in the effort to ease the shortage of human donor organs. → Read More

U.S. Supply of Effective Covid Antibody Drug Dwindling

The last doses of the drug, one of a few found to reduce the risk of severe disease even after Omicron, will be used up in late August unless Congress approves more pandemic funding, administration officials say. → Read More

CDC Recommends Moderna’s Covid-19 Vaccine for Kids 6 to 17 Years

The sign-off is the final step in allowing the shots to become widely available. → Read More

CDC Advisers Endorse Moderna’s Covid-19 Vaccine for Kids 6 to 17 Years

Advisers to the Centers for Disease Control and Prevention backed use of Moderna Inc.’s Covid-19 vaccine in children ages 6 to 17 years. → Read More

CDC Recommends Covid-19 Vaccines for Young Children

Vaccine experts advising the Centers for Disease Control and Prevention voted to recommend Covid-19 shots for young children ages 6 months to 5 years, who could potentially start receiving shots as soon as Monday. → Read More

Can We Develop a Covid-19 Vaccine That Lasts?

New variants have weakened the protection of the current shots, which require unpopular boosters. Scientists and the White House are exploring options for more durable protection, but success could take years. → Read More

CDC Advisers Reviewing Covid-19 Vaccines for Young Children

A recommendation from the advisers, who are meeting Friday and Saturday to review data around vaccinating those under 5 years old, could pave the way for expanding access to the shots. → Read More

FDA Set to Get More Power to Pull Accelerated Drugs That Don’t Work

Lawmakers are proposing giving the Food and Drug Administration added authority to make sure drugmakers conduct large follow-up studies of fast-tracked therapies → Read More

Novavax Covid-19 Vaccine Faces FDA Advisers’ Scrutiny

The outside panel of experts will vote on whether the shot should be authorized, after the agency found it effective but flagged a safety concern. → Read More

FDA Says Novavax Covid-19 Shot Effective but Signals Safety Worry

The vaccine was 90% effective, but the testing took place before Omicron, and five people who got the shots in studies had complications, the agency said. → Read More

National Baby-Formula Stockpile Is Urged by FDA Commissioner

Robert Califf also told lawmakers he expects a surplus of formula in about two months as a result of government and company efforts. → Read More

Baby Formula Makers and FDA to Discuss Shortage With Lawmakers

Officials from the FDA and from the major formula manufacturers are expected to testify before the House Energy and Commerce Committee’s oversight and investigations subcommittee about their attempts to address the short supply. → Read More